Amoxiclav

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amoxiclav

Quick Facts

Property Description
Active Ingredients Amoxicillin and Clavulanic acid (as potassium salt)
Pharmacological Class Antibacterial Agent (Beta-lactam with Beta-lactamase inhibitor)
Forms Tablets, Powder for Oral Suspension, Powder for Injection
Origin/Type Semi-synthetic / Fixed-dose Combination Product
Status Prescription-only (Rx)

Amoxiclav (generically known as Co-amoxiclav or Amoxicillin/Clavulanic acid) is a prescription-only antibacterial agent classified as a fixed-dose combination product used to fight bacterial infections. Its two active ingredients are Amoxicillin, an antibiotic from the aminopenicillin subgroup, and Clavulanic acid, which serves a protective function. This pairing defines the medication's specialized identity and is widely utilized in medical practice.

The Combination Principle and Clinical Recognition

This medication's primary purpose is to provide a broadened spectrum of activity compared to Amoxicillin when used alone. The Amoxicillin component works to kill susceptible bacteria, while the Clavulanic acid acts as a Beta-lactamase inhibitor, neutralizing the bacterial defense enzymes that would otherwise break down the antibiotic. This synergistic approach is clinically recognized for addressing the challenge of bacterial resistance, ensuring the primary antibiotic remains effective against resistant strains.

Available Preparations

Amoxiclav is essential for treating a range of bacterial infections, particularly when organisms that produce Beta-lactamase enzymes are involved. The formulation is available in forms suitable for both oral and intravenous administration. These include tablets and a powder for oral suspension to suit various patient groups, as well as a sterile powder for solution for injection or infusion for use in clinical settings.

What side effects are possible with Amoxiclav?

Possible Side Effects and Safety Information

The safety profile of Amoxiclav is defined by adverse reactions classified by frequency and body system, and formal restrictions set by regulatory agencies.

Frequency-Classified Adverse Reactions

The most frequently reported adverse events are generally related to the Gastrointestinal System. These commonly include diarrhea, loose stools, nausea, and vomiting. Skin and Subcutaneous Tissue Disorders, such as rashes and urticaria (hives), are also common.

Less common side effects may affect the Nervous System (e.g., dizziness, headache) and include indigestion. Rare and very rare events encompass more serious conditions, including severe cutaneous reactions (like Stevens-Johnson syndrome) and hematological changes (e.g., reversible leukopenia).

Serious Adverse Reactions and Contraindications

Official documents highlight the risk of serious, potentially fatal hypersensitivity reactions (anaphylaxis, angioedema) to Amoxiclav or other beta-lactam antibiotics. A prior history of these reactions or a history of cholestatic jaundice or hepatic dysfunction (liver toxicity) associated with previous Amoxiclav use are formal contraindications (absolute restrictions on use).

Other clinically significant safety concerns include:

  • Hepatobiliary Disorders: Liver dysfunction and cholestatic jaundice have been reported, necessitating immediate drug discontinuation if signs or symptoms of hepatitis occur.
  • Antibiotic-Associated Colitis: Severe diarrhea that occurs during or up to two months after treatment may be a sign of Clostridioides difficile-associated diarrhea (CDAD), which requires evaluation.
  • Mononucleosis: Amoxiclav should be avoided in patients with mononucleosis due to a high risk of developing a non-allergic skin rash.

Population and Interaction Notes

Regulatory caution is required for patients with severe renal impairment (kidney disease), as the drug is mainly eliminated by the kidneys, necessitating dose adjustments. Safety information also advises on potential interactions with oral anticoagulants (monitoring may be required due to possible prolonged bleeding time) and notes that the medicine may reduce the effectiveness of oral contraceptives.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Amoxiclav (Amoxicillin/Clavulanic acid) is officially documented to present primarily with gastrointestinal symptoms, including vomiting, diarrhea, and stomach pain, which may lead to a disturbance of fluid and electrolyte balances. Other manifestations cited in regulatory sources include sleepiness and the key clinical sign of greatly decreased frequency or amount of urination. These physiological changes require close attention and supportive treatment to manage electrolyte balance.

The potential for serious outcomes is officially recognized, particularly concerning the renal and central nervous systems. High exposures of the amoxicillin component are associated with crystalluria (crystal formation in the urine), a serious condition that may progress to acute kidney injury and renal failure. Furthermore, convulsions (seizures) may occur, especially in individuals with pre-existing impaired renal function, due to drug accumulation.

Emergency response statements from regulatory authorities mandate that an individual must seek immediate emergency help if any documented symptoms of overdose occur. In the management of a severe overdose, treatment is supportive and symptomatic. The official procedural measure for drug clearance is hemodialysis, which is documented to remove both active components from the circulation. Maintaining adequate fluid intake is also officially advised to mitigate the risk of crystalluria.

Therapeutic Uses of Amoxiclav

What Amoxiclav Treats: Main Uses and Benefits

Amoxiclav (Amoxicillin/Clavulanic acid) is commonly used for managing a range of bacterial infections across diverse clinical contexts. Its use is applicable within clinical settings that involve acute or disruptive symptom patterns, and may assist with easing symptoms related to physical discomfort and systemic imbalance. Its use is considered relevant in clinical settings that involve acute symptomatic episodes.

The medication is commonly used across conditions presenting with acute episodes, including acute bacterial sinusitis, lower respiratory tract infections, acute otitis media, and infections of the skin and skin structure. It is applied across domains where additional symptomatic support is needed.

Therapeutic Focus

This medication plays a role in managing symptoms that interfere with daily comfort, such as high fever, persistent cough, painful swelling, and severe localized pain. It is generally applied in scenarios where additional management of discomfort is required, helping to address symptom clusters that may become intense or disruptive.

“Amoxiclav is relevant when supportive symptom management is appropriate, contributing to improved comfort during periods of heightened symptoms.”

The combination is also used across conditions presenting with acute or disruptive episodes, including certain urinary tract infections and infections linked to organ-specific functional stress. It provides support that helps ease the overall symptom burden, offering symptomatic relief that may help patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Acute Distress

The medication is commonly used to help with symptoms associated with acute or episodic changes across multiple body systems, including the respiratory, otolaryngological, and cutaneous domains. Its application assists with maintaining functional stability by easing challenging localized manifestations.

Eligibility and Restrictions for Use

The eligibility for Amoxiclav (Amoxicillin/Clavulanic acid) is strictly determined by official regulatory criteria concerning patient history, age, organ function, and concurrent medical conditions.

Populations for Whom Use is Prohibited or Restricted

Category Regulatory Status
Absolute Contraindication History of a serious hypersensitivity reaction (e.g., anaphylaxis) to any penicillin or other beta-lactam antibiotic. History of cholestatic jaundice or hepatic dysfunction previously associated with Amoxiclav treatment.
Conditional Use / Avoidance Use must be avoided in patients with Infectious Mononucleosis due to the high risk of a morbilliform rash. Formulations containing aspartame are not to be used by patients with Phenylketonuria (PKU).

Age and Organ Function Constraints

Adults and Pediatric Patients are the approved populations, though specific limitations apply. Children under 40 kg require weight-based, typically liquid, formulations, as certain high-ratio tablet strengths are not recommended.

Severe Renal Impairment ( CrCl lt 30 mL/min) is a restriction requiring mandatory dose adjustment; specific extended-release formulations are contraindicated. Patients with Hepatic Impairment require use with caution and must have their liver function regularly monitored.

Pregnancy and Lactation: Use during pregnancy is generally not recommended unless the need is clearly established. Caution should be exercised when used by nursing mothers due to the excretion of components into breast milk.

What should I know about interactions with other medicines?

The official regulatory profile for Amoxiclav focuses on drug combinations that modify systemic exposure or result in specific pharmacodynamic overlap, as documented in government regulatory sources.

Pharmacokinetic and Exposure-Altering Interactions

Medicinal products that affect the renal clearance of Amoxicillin are officially documented. Co-administration with Probenecid is not recommended, as this substance inhibits the renal tubular secretion of Amoxicillin, resulting in increased and prolonged blood concentrations of the antibiotic component. Similarly, the Amoxicillin component can elevate serum concentrations of Methotrexate by inhibiting its renal elimination, a condition noted as particularly relevant for high-dose Methotrexate regimens. Furthermore, Amoxiclav may reduce the efficacy of combined Oral Contraceptives due to its potential impact on intestinal flora.

Pharmacodynamic Effects and Restrictions

Pharmacodynamic interactions are also recorded in regulatory labeling. The concomitant use of Amoxiclav and Oral Anticoagulants may increase the prolongation of prothrombin time, an important measure of clotting risk. This risk is officially noted as potentially heightened in older patients or those with liver or kidney dysfunction. Additionally, concurrent administration with Allopurinol is documented to increase the incidence of skin rashes. A formal restriction advises that use should be avoided in patients with the disease state Infectious Mononucleosis due to the documented high incidence of rash upon exposure. The product's absorption is officially influenced by meals, as taking the medication with Food is noted to optimize the absorption of the clavulanic acid component.

Mechanism of Action

Disrupting Bacterial Cell Wall Construction

Amoxiclav operates through a dual mechanistic synergy targeting two distinct bacterial processes. The amoxicillin component acts by forming a strong, irreversible covalent bond with specific bacterial enzymes known as Penicillin-Binding Proteins (PBPs). These PBPs are critical for cross-linking the peptidoglycan layer during cell wall synthesis. By inhibiting this key molecular process, the drug causes critical structural failure, leading to the rapid and lethal lysis (rupture) of the susceptible bacterial cell.

Neutralizing Bacterial Defense Enzymes ️

The second component, clavulanic acid, functions as an irreversible suicide inhibitor against beta-lactamase enzymes. These enzymes are bacterial defenses designed to hydrolyze and inactivate the amoxicillin molecule. By deactivating the beta-lactamases, clavulanic acid shields the amoxicillin, allowing the cell-wall-disrupting mechanism to proceed unimpeded against susceptible populations. This combined molecular cascade results in the swift bactericidal effect and subsequent clearance of susceptible bacterial cells.

Dosage and Administration Information

How Amoxiclav is Used: Official Administration Guidelines

The proper administration of Amoxiclav (Amoxicillin/Clavulanic acid) is defined strictly by official documents, detailing the routes, dosage regimens, and conditions for use. This section outlines how the medication is administered in clinical practice.

Official Routes and Timing

Amoxiclav is approved for both oral and intravenous (IV) administration. The choice of route depends on the severity of the infection and patient tolerance. Oral formulations, such as tablets and suspensions, must be taken at the start of a meal. This instruction is given to optimize the absorption of the active components and minimize gastrointestinal effects.

Administration Detail Official Guideline
Oral Frequency Typically every 8 hours or every 12 hours.
IV Frequency Typically every 6 to 8 hours.
Dose Example (Oral) 875 mg/125 mg of Amoxicillin/Clavulanic acid.

Treatment Duration and Specific Conditions

A course of treatment with Amoxiclav typically lasts from 7 to 10 days but generally should not exceed 14 days without clinical reassessment. The full prescribed course must be completed, even if symptoms improve earlier.

Specialized instructions govern the preparation of formulations:

  • Oral Suspension: Must be fully reconstituted with water and shaken before use.
  • IV Infusion: Must be administered slowly, typically over 30 to 40 minutes, and the solution must be prepared immediately before use.

Dosing Adjustments

Official guidelines mandate dose adjustments for certain patient populations. For adults with moderate to severe renal impairment (creatinine clearance less than or equal to 30 mL/min), the dose and frequency must be significantly reduced. Pediatric dosing is determined based on the child’s body weight (in mg/kg/day) and the severity of the infection.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Amoxiclav

Evidence for Use in Treating Ear, Nose, and Throat Infections

This section will summarize the research studies and clinical trials that was studied for scenarios involving common bacterial infections of the ear, nose, and throat, such as acute bacterial sinusitis and otitis media. The focus will be on explaining what kinds of studies exist and the research scenarios that were explored.

Research has evaluated Amoxiclav in adults and children with conditions involving periods of heightened symptoms in the ear, nose, and throat area. For infections like otitis media, which is a condition associated with acute or disruptive episodes, studies examined how Amoxiclav was studied alongside other therapeutic approaches or an inactive treatment (placebo). The findings describe patterns observed in the studies related to changes observed in measured outcomes and outcomes reflecting daily functioning or activity level.

Evidence for Use in Treating Lower Respiratory Tract Infections

This part will present an overview of the scientific evidence, including randomized controlled trials, related to research scenarios involving bacterial infections of the lungs and airways, specifically community-acquired pneumonia and acute exacerbations of chronic bronchitis. Amoxiclav was studied for conditions marked by functional limitations and outcomes linked to inflammatory or irritative states in the lower respiratory tract. Research highlights changes measured during the study period, which contributes to the broader evidence landscape.

⏳ Long-term Studies and Follow-up

Research related to long-term study findings after exposure to Amoxiclav is limited. Most available studies are designed to focus on the immediate recovery from an acute infection, meaning follow-up durations were limited. There are few comprehensive trials that were observed in patients for extended periods to evaluate patterns of response over time or monitor for the return of studied outcomes. Currently, long-term effects are not fully established, and there is limited information for long-term outcomes across many of the studied conditions.

What is Still Uncertain about Amoxiclav

Research exploring the use of Amoxiclav still contains several key gaps. Findings were mixed or inconsistent findings have been reported when comparing Amoxiclav's studied outcomes to those of certain newer or alternative treatments, indicating that comparative evidence is lacking in some contexts. The evidence quality varies across studies, and sample sizes were modest in some research scenarios, which contributes to the areas of uncertainty. More research is ongoing and is needed to clarify the full range of outcomes studied, particularly in specific subgroups where subgroup findings are uncertain.

Key Studies & References Summary of Product Characteristics (SmPC) for Amoxicillin/Clavulanate (HPRA)

Frequently Asked Questions (FAQ)

Common questions about Amoxiclav (FAQ)


Q: Does Amoxiclav affect the balance of bacteria in my gut?

Official product information indicates that using antibacterial agents like Amoxiclav may lead to changes in the body’s normal balance of bacterial flora (microorganisms). This alteration can potentially cause gastrointestinal issues such as diarrhea. Regulatory documents note that in rare cases, this change in gut flora has been associated with a more serious condition known as Clostridioides difficile-associated diarrhea (CDAD).


Q: Are there any common pain relievers that should be avoided while taking Amoxiclav?

Regulatory documents indicate that the use of Amoxiclav alongside oral anticoagulants (blood thinners) may heighten the risk of bleeding. This risk is noted as potentially greater when other medicines that prevent blood clotting, such as non-steroidal anti-inflammatory drugs (NSAIDs like ibuprofen), are used concurrently. The complete interactions section contains further details about this topic.


Q: What should I do if I forget a dose of Amoxiclav?

According to official patient information, if a dose is forgotten, it is generally advised to take it as soon as it is remembered. However, it is advised to then wait at least four hours before taking the next dose. If it is almost time for the next scheduled dose, the missed dose may be left out to maintain the appropriate dosing interval.


Q: What if I take too much Amoxiclav by accident?

Official labeling on accidental overdose states that it may be associated with signs such as gastrointestinal problems like stomach pain, vomiting, and diarrhea. Other effects observed include sleepiness or potential effects on the kidneys. In rare instances, excessive intake has been linked to convulsions (seizures).


Q: Can Amoxiclav be crushed or split?

The official documentation for certain formulations, such as extended-release tablets, explicitly states that they must not be crushed, chewed, or split according to the regulatory directions. This is because modifying the tablet would interfere with the controlled-release mechanism of the medication.


Q: What is the purpose of the different strengths of Amoxiclav (e.g., 500mg/125mg)?

The various fixed ratios and strengths are designed to provide a variety of dosing options, which allows the prescriber to deliver the necessary dose of the amoxicillin (the active antibiotic) while limiting the daily amount of the clavulanic acid component. Regulatory information specifies that the different ratios are not interchangeable.


Q: Can taking Amoxiclav cause yeast infections in women?

Yes, official adverse reaction reports list side effects in the 'Infections and Infestations' system organ class, including mucocutaneous candidiasis. This is commonly known as a yeast infection (or thrush) and is a possible consequence of the antibiotic altering the natural balance of microorganisms in the body.


Q: Does Amoxiclav interfere with any common blood tests?

Official information indicates that the clavulanic acid component can cause a false positive result in a blood test called the Coombs test. Laboratory personnel should be informed that a patient is taking this medicine before the test.


Q: How is Amoxiclav usually eliminated from the body?

The active components of Amoxiclav are primarily removed from the body through the kidneys (renal excretion). Regulatory documents state that a significant portion of both amoxicillin and clavulanic acid is excreted unchanged in the urine within the first few hours after administration.


Q: What are the signs of a severe allergic reaction to Amoxiclav that require immediate attention?

Signs of a serious allergic reaction (hypersensitivity) described in the official drug documentation include a widespread rash, hives, swelling of the face, lips, tongue, or throat, or experiencing trouble breathing. These are signs that are noted in regulatory information as requiring medical assessment.


Q: Why do some people need Amoxiclav while others just take amoxicillin?

The combination product is generally used when an infection is caused by bacteria that are known or suspected to produce beta-lactamase enzymes. Clavulanic acid acts as a shield, protecting the amoxicillin from being broken down by these bacterial defense enzymes, which extends the spectrum of infections it is studied for.


Q: Is it possible to be allergic to Amoxiclav without being allergic to penicillin?

Yes, official documentation lists several restrictions on use that are not solely related to penicillin. These include a history of a hypersensitivity reaction to any of the non-active components (excipients), as well as a history of liver dysfunction previously associated with Amoxiclav treatment specifically.


Q: Can Amoxiclav cause insomnia or difficulty sleeping?

Official adverse reaction tables list effects on the nervous system, such as dizziness and headache, as less common effects. In addition, insomnia (difficulty sleeping) has been reported in post-marketing experience with medicines containing a beta-lactamase inhibitor.


Q: Is a fever a potential side effect of Amoxiclav?

Yes, official regulatory texts describe fever as a possible symptom associated with certain rare and severe adverse reactions, such as drug reaction with eosinophilia and systemic symptoms (DRESS) or acute generalized exanthematous pustulosis (AGEP). Fever itself is not typically listed as a common side effect.


Q: What does the term 'beta-lactamase inhibitor' mean in relation to Amoxiclav?

This term describes the pharmacological class of the clavulanic acid component. A beta-lactamase inhibitor is a molecule that works to deactivate the beta-lactamase enzymes that some bacteria produce. By neutralizing this bacterial defense, it protects the amoxicillin and allows it to successfully attack susceptible bacterial cells.


Q: Is it safe to drive or operate machinery while taking Amoxiclav?

Official warnings state that adverse reactions such as dizziness and, rarely, convulsions (seizures), may occur. Patients experiencing these effects may have an impaired ability to drive or operate machinery, as noted in official warnings.


Q: Do studies show that Amoxiclav is effective for dental infections?

Yes, regulatory documents in some regions list specific dental conditions, such as severe dental abscess with spreading cellulitis, as one of the established clinical indications for which Amoxiclav has been approved for use.

How should Amoxiclav be stored and disposed of?

How to Store and Dispose of Amoxiclav?

The storage requirements for Amoxiclav (Amoxicillin/Clavulanate Potassium) depend strictly on the formulation.

Formulation Storage Conditions
Tablets/Dry Powder Store at room temperature (typically 20 C to 25 C), protected from moisture and heat, in the tightly closed original container.
Reconstituted Liquid Must be refrigerated immediately after mixing (e.g., 2 C to 8 C). Do not freeze.

The reconstituted liquid suspension has a short stability period and must be discarded after 10 to 14 days, even if there is medication remaining. Intravenous preparations must be used immediately after reconstitution. All forms must be stored out of the sight and reach of children. Unused or expired medication should be disposed of properly according to local guidelines to minimize environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amoxiclav found in:

A-Z Index: